arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Quince Therapeutics, Inc.

QNCX
$30.43 ▲ +0.75 (+2.51%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
34 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
72
Health
Good
Bullish
auto_awesome

Analytical Summary

Quince Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $277.5M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -73.5%
FCF / Share $-0.84
Trailing P/E 8.5x
Price / Book 26.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

34-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$35.91M
↑ +191.0%
FCF / Share Free cash flow per share
$-0.84
↓ -276.9%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
100
Financial Health
53
Cash Quality
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters